1887

Microbiology Society logo

Volume 158, Issue 2

Construction of as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Free

Abstract

We sought to develop (BI) as a vehicle for the expression of heterologous antigens. Two proteins of enterotoxigenic (ETEC) were expressed in BI: CfaB, a major fimbrial subunit protein, and LTB, the B subunit of heat-labile enterotoxin. The expression of CfaB and LTB in BI was verified by electrophoretic analysis. Sprague–Dawley rats were then subjected to intragastric immunization with BI-CfaB and BI-LTB systems both separately and together. ELISA was used to characterize the serum and mucosal immune responses against ETEC antigens. The immunized rats were intraperitoneally challenged with wild-type ETEC H10407 to study the immune response . The serum titres of IgG and faecal IgA antibodies in the BI-CfaB plus BI-LTB mixed vaccination group were significantly greater than those in the other two groups, which were immunized with a single vaccine (<0.05). However, no significant difference was seen between the two groups that received a single immunization. These results suggest that expressing CfaB and LTB in BI provides a probiotic system with immunogenic properties. Furthermore, the expression of LTB in BI preserved its mucosal adjuvant effect. So this study confirms that BI can be used as a novel oral vaccine expression system for a heterologous antigen and BI-LTB can provide mucosal adjuvant properties.

  • Received:
  • Accepted:
  • Revised:
  • Published Online:
© 2012 SGM
Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.049932-0
2012-02-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/micro/158/2/498.html?itemId=/content/journal/micro/10.1099/mic.0.049932-0&mimeType=html&fmt=ahah

References

  1. Adachi J. A., Jiang Z., Cox M., Wood L., DuPont H. L., Mathewson J. J. ( 2000). Serum antibody response induced in mice after oral administration of three different antigens of enterotoxigenic Escherichia coli in enteric coated microparticles. J Travel Med 7:304–308 [View Article][PubMed]
     [Google Scholar]
  2. Barry E. M., Altboum Z., Losonsky G., Levine M. M. ( 2003). Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine 21:333–340 [View Article][PubMed]
     [Google Scholar]
  3. Bermúdez-Humarán L. G. ( 2009). Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 5:264–267 [View Article][PubMed]
     [Google Scholar]
  4. Bhaskaran S., Jay C. M., Berghman L. R., Wagner G. G., Waghela S. D. ( 2005). A single-chain fragment variable recombinant antibody against F5 fimbria of enterotoxigenic Escherichia coli inhibits agglutination of horse red blood cells induced by F5 protein. Vet Res Commun 29:463–476 [View Article][PubMed]
     [Google Scholar]
  5. Boedeker E. C. ( 2005). Vaccines for enterotoxigenic Escherichia coli: current status. Curr Opin Gastroenterol 21:15–19[PubMed]
     [Google Scholar]
  6. Bühler T., Hoschützky H., Jann K. ( 1991). Analysis of colonization factor antigen I, an adhesin of enterotoxigenic Escherichia coli O78 : H11: fimbrial morphology and location of the receptor-binding site. Infect Immun 59:3876–3882[PubMed]
     [Google Scholar]
  7. Byrd W., Cassels F. J. ( 2006). The encapsulation of enterotoxigenic Escherichia coli colonization factor CS3 in biodegradable microspheres enhances the murine antibody response following intranasal administration. Microbiology 152:779–786 [View Article][PubMed]
     [Google Scholar]
  8. Daley A., Randall R., Darsley M., Choudhry N., Thomas N., Sanderson I. R., Croft N. M., Kelly P. ( 2007). Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. Gut 56:1550–1556 [View Article][PubMed]
     [Google Scholar]
  9. DuPont H. L. ( 2008). Systematic review: prevention of travellers’ diarrhoea. Aliment Pharmacol Ther 27:741–751 [View Article][PubMed]
     [Google Scholar]
  10. Gaastra W., Svennerholm A. M. ( 1996). Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol 4:444–452 [View Article][PubMed]
     [Google Scholar]
  11. Girard M. P., Steele D., Chaignat C. L., Kieny M. P. ( 2006). A review of vaccine research and development: human enteric infections. Vaccine 24:2732–2750 [View Article][PubMed]
     [Google Scholar]
  12. Guarner F., Malagelada J. R. ( 2003). Gut flora in health and disease. Lancet 361:512–519 [View Article][PubMed]
     [Google Scholar]
  13. Hanniffy S. B., Carter A. T., Hitchin E., Wells J. M. ( 2007). Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 195:185–193 [View Article][PubMed]
     [Google Scholar]
  14. Johnson A. M., Kaushik R. S., Francis D. H., Fleckenstein J. M., Hardwidge P. R. ( 2009). Heat-labile enterotoxin promotes Escherichia coli adherence to intestinal epithelial cells. J Bacteriol 191:178–186 [View Article][PubMed]
     [Google Scholar]
  15. Lee J. C., Park J. S., Shepherd S. E., Carey V., Fattom A. ( 1997). Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 65:4146–4151[PubMed]
     [Google Scholar]
  16. Levine M. M., Nalin D. R., Hoover D. L., Bergquist E. J., Hornick R. B., Young C. R. ( 1979). Immunity to enterotoxigenic Escherichia coli . Infect Immun 23:729–736[PubMed]
     [Google Scholar]
  17. Liu J. K., Hou X. L., Wei C. H., Yu L. Y., He X. J., Wang G. H., Lee J. S., Kim C. J. ( 2009). Induction of immune responses in mice after oral immunization with recombinant Lactobacillus casei strains expressing enterotoxigenic Escherichia coli F41 fimbrial protein. Appl Environ Microbiol 75:4491–4497 [View Article][PubMed]
     [Google Scholar]
  18. López-Gigosos R., García-Fortea P., Reina-Doña E., Plaza-Martín E. ( 2007). Effectiveness in prevention of travellers’ diarrhoea by an oral cholera vaccine WC/rBS. Travel Med Infect Dis 5:380–384 [View Article][PubMed]
     [Google Scholar]
  19. Lund B. M., Baird-Parker T. C., Gould G. W. ( 2000). Microbiological Safety and Quality of Food vol. 2 Gaithersburg, MD: Aspen Publishers;
     [Google Scholar]
  20. Medina M., Vintiñi E., Villena J., Raya R., Alvarez S. ( 2010). Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections. Bioeng Bugs 1:313–325 [View Article][PubMed]
     [Google Scholar]
  21. O’Sullivan D. J., Klaenhammer T. R. ( 1993). Rapid mini-prep isolation of high-quality plasmid DNA from lactococcus and Lactobacillus spp.. Appl Environ Microbiol 59:2730–2733[PubMed]
     [Google Scholar]
  22. Pascual D. W., Hone D. M., Hall S., van Ginkel F. W., Yamamoto M., Walters N., Fujihashi K., Powell R. J., Wu S. & other authors ( 1999). Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response. Infect Immun 67:6249–6256[PubMed]
     [Google Scholar]
  23. Pizza M., Giuliani M. M., Fontana M. R., Monaci E., Douce G., Dougan G., Mills K. H., Rappuoli R., Del Giudice G. ( 2001). Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534–2541 [View Article][PubMed]
     [Google Scholar]
  24. Sack R. B. ( 1975). Human diarrheal disease caused by enterotoxigenic Escherichia coli . Annu Rev Microbiol 29:333–353 [View Article][PubMed]
     [Google Scholar]
  25. Steinsland H., Valentiner-Branth P., Perch M., Dias F., Fischer T. K., Aaby P., Mølbak K., Sommerfelt H. ( 2002). Enterotoxigenic Escherichia coli infections and diarrhea in a cohort of young children in Guinea-Bissau. J Infect Dis 186:1740–1747 [View Article][PubMed]
     [Google Scholar]
  26. Uesaka Y., Otsuka Y., Lin Z., Yamasaki S., Yamaoka J., Kurazono H., Takeda Y. ( 1994). Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose. Microb Pathog 16:71–76 [View Article][PubMed]
     [Google Scholar]
  27. Wang L., Huang J. A., Nagesha H. S., Smith S. C., Phelps A., Holmes I., Martyn J. C., Coloe P. J., Reeves P. R. ( 1999). Bacterial expression of the major antigenic regions of porcine rotavirus VP7 induces a neutralizing immune response in mice. Vaccine 17:2636–2645 [View Article][PubMed]
     [Google Scholar]
  28. Wei C. H., Liu J. K., Hou X. L., Yu L. Y., Lee J. S., Kim C. J. ( 2010). Immunogenicity and protective efficacy of orally or intranasally administered recombinant Lactobacillus casei expressing ETEC K99. Vaccine 28:4113–4118 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.049932-0
Loading
Construction of Bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli
Microbiology 158, 498 (2012); https://doi.org/10.1099/mic.0.049932-0
/content/journal/micro/10.1099/mic.0.049932-0
/content/journal/micro/10.1099/mic.0.049932-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error